The protective effect of fibroblast growth factor‐21 in alcoholic cardiomyopathy: a role in protecting cardiac mitochondrial function
Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality. Fibroblast growth factor 21 (FGF21) is a well‐established cardioprotective factor. We aimed to study the role of FGF21 in experimentally induced...
Saved in:
Published in | The Journal of pathology Vol. 253; no. 2; pp. 198 - 208 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.02.2021
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality. Fibroblast growth factor 21 (FGF21) is a well‐established cardioprotective factor. We aimed to study the role of FGF21 in experimentally induced models and clinical affected patients with cardiac damage due to chronic alcohol consumption. We found that circulating FGF21 levels and cardiac FGF21 and β‐klotho protein levels were increased in subjects with chronic alcohol consumption. As an experimental model of ACM, we fed wild‐type and Fgf21 knockout (Fgf21−/−) mice with a 4% alcohol liquid diet for 4 and 12 weeks. FGF21 circulating levels and FGF21 expression in the myocardium were also increased in wild‐type mice after chronic alcohol intake. Fgf21−/− mice develop a higher degree of cardiac hypertrophy, fibrosis, and cardiac dysfunction after chronic alcohol consumption than wild‐type mice. Moreover, the myocardium of Fgf21−/− mice showed signs of metabolic deregulation, oxidative stress, and mitochondrial dysfunction after alcohol intake. Finally, human cardiac biopsies from patients with chronic alcohol consumption developing ACM presented a higher degree of oxidative stress which positively correlated with the FGF21 protein levels in the myocardium. We conclude that plasma levels and cardiac myocyte FGF21 expression were induced in response to chronic alcohol consumption. The lack of FGF21 aggravated cardiac damage produced by ACM, in association with enhanced mitochondrial and oxidative stress, thus pointing to FGF21 as a protective agent against development of alcohol‐induced cardiomyopathy. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
---|---|
AbstractList | Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality. Fibroblast growth factor 21 (FGF21) is a well‐established cardioprotective factor. We aimed to study the role of FGF21 in experimentally induced models and clinical affected patients with cardiac damage due to chronic alcohol consumption. We found that circulating FGF21 levels and cardiac FGF21 and β‐klotho protein levels were increased in subjects with chronic alcohol consumption. As an experimental model of ACM, we fed wild‐type and Fgf21 knockout (
Fgf21
−/−
) mice with a 4% alcohol liquid diet for 4 and 12 weeks. FGF21 circulating levels and FGF21 expression in the myocardium were also increased in wild‐type mice after chronic alcohol intake.
Fgf21
−/−
mice develop a higher degree of cardiac hypertrophy, fibrosis, and cardiac dysfunction after chronic alcohol consumption than wild‐type mice. Moreover, the myocardium of
Fgf21
−/−
mice showed signs of metabolic deregulation, oxidative stress, and mitochondrial dysfunction after alcohol intake. Finally, human cardiac biopsies from patients with chronic alcohol consumption developing ACM presented a higher degree of oxidative stress which positively correlated with the FGF21 protein levels in the myocardium. We conclude that plasma levels and cardiac myocyte FGF21 expression were induced in response to chronic alcohol consumption. The lack of FGF21 aggravated cardiac damage produced by ACM, in association with enhanced mitochondrial and oxidative stress, thus pointing to FGF21 as a protective agent against development of alcohol‐induced cardiomyopathy. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality. Fibroblast growth factor 21 (FGF21) is a well‐established cardioprotective factor. We aimed to study the role of FGF21 in experimentally induced models and clinical affected patients with cardiac damage due to chronic alcohol consumption. We found that circulating FGF21 levels and cardiac FGF21 and β‐klotho protein levels were increased in subjects with chronic alcohol consumption. As an experimental model of ACM, we fed wild‐type and Fgf21 knockout (Fgf21−/−) mice with a 4% alcohol liquid diet for 4 and 12 weeks. FGF21 circulating levels and FGF21 expression in the myocardium were also increased in wild‐type mice after chronic alcohol intake. Fgf21−/− mice develop a higher degree of cardiac hypertrophy, fibrosis, and cardiac dysfunction after chronic alcohol consumption than wild‐type mice. Moreover, the myocardium of Fgf21−/− mice showed signs of metabolic deregulation, oxidative stress, and mitochondrial dysfunction after alcohol intake. Finally, human cardiac biopsies from patients with chronic alcohol consumption developing ACM presented a higher degree of oxidative stress which positively correlated with the FGF21 protein levels in the myocardium. We conclude that plasma levels and cardiac myocyte FGF21 expression were induced in response to chronic alcohol consumption. The lack of FGF21 aggravated cardiac damage produced by ACM, in association with enhanced mitochondrial and oxidative stress, thus pointing to FGF21 as a protective agent against development of alcohol‐induced cardiomyopathy. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality. Fibroblast growth factor 21 (FGF21) is a well-established cardioprotective factor. We aimed to study the role of FGF21 in experimentally induced models and clinical affected patients with cardiac damage due to chronic alcohol consumption. We found that circulating FGF21 levels and cardiac FGF21 and β-klotho protein levels were increased in subjects with chronic alcohol consumption. As an experimental model of ACM, we fed wild-type and Fgf21 knockout (Fgf21 ) mice with a 4% alcohol liquid diet for 4 and 12 weeks. FGF21 circulating levels and FGF21 expression in the myocardium were also increased in wild-type mice after chronic alcohol intake. Fgf21 mice develop a higher degree of cardiac hypertrophy, fibrosis, and cardiac dysfunction after chronic alcohol consumption than wild-type mice. Moreover, the myocardium of Fgf21 mice showed signs of metabolic deregulation, oxidative stress, and mitochondrial dysfunction after alcohol intake. Finally, human cardiac biopsies from patients with chronic alcohol consumption developing ACM presented a higher degree of oxidative stress which positively correlated with the FGF21 protein levels in the myocardium. We conclude that plasma levels and cardiac myocyte FGF21 expression were induced in response to chronic alcohol consumption. The lack of FGF21 aggravated cardiac damage produced by ACM, in association with enhanced mitochondrial and oxidative stress, thus pointing to FGF21 as a protective agent against development of alcohol-induced cardiomyopathy. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality. Fibroblast growth factor 21 (FGF21) is a well-established cardioprotective factor. We aimed to study the role of FGF21 in experimentally induced models and clinical affected patients with cardiac damage due to chronic alcohol consumption. We found that circulating FGF21 levels and cardiac FGF21 and β-klotho protein levels were increased in subjects with chronic alcohol consumption. As an experimental model of ACM, we fed wild-type and Fgf21 knockout (Fgf21-/- ) mice with a 4% alcohol liquid diet for 4 and 12 weeks. FGF21 circulating levels and FGF21 expression in the myocardium were also increased in wild-type mice after chronic alcohol intake. Fgf21-/- mice develop a higher degree of cardiac hypertrophy, fibrosis, and cardiac dysfunction after chronic alcohol consumption than wild-type mice. Moreover, the myocardium of Fgf21-/- mice showed signs of metabolic deregulation, oxidative stress, and mitochondrial dysfunction after alcohol intake. Finally, human cardiac biopsies from patients with chronic alcohol consumption developing ACM presented a higher degree of oxidative stress which positively correlated with the FGF21 protein levels in the myocardium. We conclude that plasma levels and cardiac myocyte FGF21 expression were induced in response to chronic alcohol consumption. The lack of FGF21 aggravated cardiac damage produced by ACM, in association with enhanced mitochondrial and oxidative stress, thus pointing to FGF21 as a protective agent against development of alcohol-induced cardiomyopathy. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality. Fibroblast growth factor 21 (FGF21) is a well-established cardioprotective factor. We aimed to study the role of FGF21 in experimentally induced models and clinical affected patients with cardiac damage due to chronic alcohol consumption. We found that circulating FGF21 levels and cardiac FGF21 and β-klotho protein levels were increased in subjects with chronic alcohol consumption. As an experimental model of ACM, we fed wild-type and Fgf21 knockout (Fgf21-/- ) mice with a 4% alcohol liquid diet for 4 and 12 weeks. FGF21 circulating levels and FGF21 expression in the myocardium were also increased in wild-type mice after chronic alcohol intake. Fgf21-/- mice develop a higher degree of cardiac hypertrophy, fibrosis, and cardiac dysfunction after chronic alcohol consumption than wild-type mice. Moreover, the myocardium of Fgf21-/- mice showed signs of metabolic deregulation, oxidative stress, and mitochondrial dysfunction after alcohol intake. Finally, human cardiac biopsies from patients with chronic alcohol consumption developing ACM presented a higher degree of oxidative stress which positively correlated with the FGF21 protein levels in the myocardium. We conclude that plasma levels and cardiac myocyte FGF21 expression were induced in response to chronic alcohol consumption. The lack of FGF21 aggravated cardiac damage produced by ACM, in association with enhanced mitochondrial and oxidative stress, thus pointing to FGF21 as a protective agent against development of alcohol-induced cardiomyopathy. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
Author | Villarroya, Francesc Ferrer‐Curriu, Gemma Crispi, Fatima Planavila, Anna Zamora, Monica Fernández‐Solà, Joaquim Garrabou, Gloria Guitart‐Mampel, Mariona Rupérez, Celia |
Author_xml | – sequence: 1 givenname: Gemma surname: Ferrer‐Curriu fullname: Ferrer‐Curriu, Gemma organization: CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) – sequence: 2 givenname: Mariona surname: Guitart‐Mampel fullname: Guitart‐Mampel, Mariona organization: University of Barcelona, Internal Medicine Service – Hospital Clínic of Barcelona, Barcelona and CIBERER – sequence: 3 givenname: Celia surname: Rupérez fullname: Rupérez, Celia organization: CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) – sequence: 4 givenname: Monica surname: Zamora fullname: Zamora, Monica organization: Institut Clinic de Ginecologia, Obstetricia i Neonatalogia, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona – sequence: 5 givenname: Fatima surname: Crispi fullname: Crispi, Fatima organization: Institut Clinic de Ginecologia, Obstetricia i Neonatalogia, Institut d'Investigacions Biomediques August Pi i Sunyer, University of Barcelona – sequence: 6 givenname: Francesc surname: Villarroya fullname: Villarroya, Francesc organization: CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) – sequence: 7 givenname: Joaquim surname: Fernández‐Solà fullname: Fernández‐Solà, Joaquim organization: CIBEROBN Fisiopatología de la Obesidad y la Nutrición, Instituto Carlos III – sequence: 8 givenname: Gloria surname: Garrabou fullname: Garrabou, Gloria email: garrabou@clinic.cat organization: University of Barcelona, Internal Medicine Service – Hospital Clínic of Barcelona, Barcelona and CIBERER – sequence: 9 givenname: Anna orcidid: 0000-0001-5474-4724 surname: Planavila fullname: Planavila, Anna email: aplanavila@ub.edu organization: CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33125701$$D View this record in MEDLINE/PubMed |
BookMark | eNp90UFvFCEUB3Biauy2evALGBIv9jAtDAMs3prGWpMmeljPE2CgQ8PACkybvXnz6mf0k8i4rYcmeoLk_d7LP-8dgYMQgwHgNUanGKH2bCvLeEopJ8_ACiPBGrEW7ACsaq1tSIf5ITjK-RYhJASlL8AhIbilHOEV-LEZDdymWIwu7s5AY239wWihdSpF5WUu8CbF-zJCK3WJ6df3ny2GLkDpdRyjdxpqmQYXp11cguzeQwlT9GYxj5PDzR5JDSdXoh5jGJKTHto51HIML8FzK302rx7eY_D18sPm4qq5_vzx08X5daMJJaThRA3GUrbGHVMWIyaYGjiTbN0iboVppVScciaw1h2VRrGBK6Yw0xpbNHTkGLzbz63Jvs0ml35yWRvvZTBxzn3bUdZhxMVC3z6ht3FOoaarivMaYY1IVW8e1KwmM_Tb5CaZdv3jiis42QOdYs7J2L8Eo345X79srV_OV-3ZE6tdkct-SpLO_6_j3nmz-_fo_sv55upPx28g3a7Q |
CitedBy_id | crossref_primary_10_1016_j_isci_2024_110389 crossref_primary_10_1111_acer_15391 crossref_primary_10_1016_j_gendis_2023_05_019 crossref_primary_10_3389_fendo_2021_802541 crossref_primary_10_3389_fonc_2022_832804 crossref_primary_10_1002_ctm2_1806 crossref_primary_10_1111_jcmm_17318 crossref_primary_10_3389_fcvm_2022_962561 crossref_primary_10_3390_jcm11030580 crossref_primary_10_1002_path_5654 crossref_primary_10_3390_cells11162576 crossref_primary_10_1002_wsbm_1549 crossref_primary_10_1097_CM9_0000000000001890 crossref_primary_10_1016_j_ijbiomac_2024_136911 crossref_primary_10_1002_path_6193 crossref_primary_10_1155_2022_5042762 crossref_primary_10_3390_ijms222212341 crossref_primary_10_1016_j_intimp_2024_111925 crossref_primary_10_3389_fcvm_2021_720581 crossref_primary_10_1016_j_cellsig_2024_111379 crossref_primary_10_1016_j_cstres_2024_03_009 crossref_primary_10_1161_CIRCHEARTFAILURE_121_008910 crossref_primary_10_1186_s12985_024_02605_6 |
Cites_doi | 10.2459/JCM.0b013e32833833a3 10.1371/journal.pone.0129791 10.1136/heartjnl-2017-312384 10.1016/j.ijcard.2018.02.109 10.1016/j.yjmcc.2010.03.017 10.1016/j.cmet.2013.08.014 10.3389/fendo.2015.00133 10.3389/fendo.2014.00107 10.3390/nu12020572 10.1038/ncomms3019 10.1016/j.cmet.2015.12.008 10.1002/hep.27060 10.1016/j.yjmcc.2008.02.276 10.1016/j.cmet.2014.02.004 10.1172/JCI31044 10.1042/CS20170271 10.1378/chest.121.5.1638 10.1212/WNL.0000000000003374 10.1093/cvr/cvu263 10.1016/j.bbalip.2004.11.004 10.1111/acer.12111 10.1002/path.5226 10.1016/j.yjmcc.2013.02.005 10.1161/CIRCULATIONAHA.108.845792 10.1016/j.jchf.2014.07.014 10.1016/j.molmet.2018.03.010 10.1016/j.cmet.2017.04.009 10.1186/s12933-015-0190-7 10.3390/ijms17101651 10.1016/0002-8703(93)90175-9 10.1097/HJH.0000000000000493 10.1152/ajpheart.00214.2016 10.1016/j.freeradbiomed.2010.07.020 10.1016/j.molmet.2017.08.004 10.1159/000486127 10.1038/srep31026 10.1073/pnas.1611243113 10.1136/heartjnl-2018-314443 10.1111/apha.12698 |
ContentType | Journal Article |
Copyright | 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2021 Pathological Society of Great Britain and Ireland |
Copyright_xml | – notice: 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. – notice: Copyright © 2021 Pathological Society of Great Britain and Ireland |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7T5 7TK 7TM 7TO 8FD FR3 H94 K9. P64 RC3 7X8 |
DOI | 10.1002/path.5573 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Chemoreception Abstracts Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1096-9896 |
EndPage | 208 |
ExternalDocumentID | 33125701 10_1002_path_5573 PATH5573 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Ministerio de Ciencia e Innovación funderid: RTI2018‐096137‐B‐I00; RYC‐2014‐16572; SAF2017‐85722‐R |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1KJ 1L6 1OB 1OC 1ZS 29L 31~ 33P 3O- 3SF 3UE 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA GSXLS H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M J5H JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M68 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 SAMSI SUPJJ SV3 TEORI UB1 V2E VH1 W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 XPP XV2 YQI YQJ ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QP 7QR 7T5 7TK 7TM 7TO 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 H94 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c3533-73bdef568146bf10696bd76a68207f9e2aab757691cc45aeb6d7b6b16cc1f0d43 |
IEDL.DBID | DR2 |
ISSN | 0022-3417 1096-9896 |
IngestDate | Fri Jul 11 16:04:25 EDT 2025 Fri Jul 25 12:17:06 EDT 2025 Thu Apr 03 07:03:11 EDT 2025 Thu Apr 24 22:50:58 EDT 2025 Tue Jul 01 04:21:19 EDT 2025 Wed Jan 22 16:32:03 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | alcohol hypertrophy mitochondria alcoholic cardiomyopathy fibrosis heart oxidative stress FGF21 |
Language | English |
License | 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3533-73bdef568146bf10696bd76a68207f9e2aab757691cc45aeb6d7b6b16cc1f0d43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-5474-4724 |
PMID | 33125701 |
PQID | 2477814803 |
PQPubID | 1006392 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2456410794 proquest_journals_2477814803 pubmed_primary_33125701 crossref_primary_10_1002_path_5573 crossref_citationtrail_10_1002_path_5573 wiley_primary_10_1002_path_5573_PATH5573 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2021 2021-02-00 20210201 |
PublicationDateYYYYMMDD | 2021-02-01 |
PublicationDate_xml | – month: 02 year: 2021 text: February 2021 |
PublicationDecade | 2020 |
PublicationPlace | Chichester, UK |
PublicationPlace_xml | – name: Chichester, UK – name: England – name: Bognor Regis |
PublicationTitle | The Journal of pathology |
PublicationTitleAlternate | J Pathol |
PublicationYear | 2021 |
Publisher | John Wiley & Sons, Ltd Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Ltd – name: Wiley Subscription Services, Inc |
References | 2010; 11 2017; 6 2015; 14 2015; 6 2013; 4 2015; 3 2018; 260 2017; 25 2018; 104 2015; 33 2015; 10 2019; 248 2020; 12 2015; 106 2017; 131 1993; 125 2016; 17 2014; 60 2013; 18 2016; 6 2010; 49 2013; 37 2013; 59 2014; 5 2007; 117 2014; 2 2018; 139 2002; 121 2016; 217 2016; 113 2016; 87 2016; 310 2008; 44 2014; 19 2018; 11 2005; 1687 2011; 123 2016; 23 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Laurent D (e_1_2_7_35_1) 2014; 2 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 33630303 - J Pathol. 2021 Jul;254(3):213-215 |
References_xml | – volume: 125: start-page: 808 year: 1993 end-page: 817 article-title: Clinical and histologic features of alcohol drinkers with congestive heart failure publication-title: Am Heart J – volume: 17: start-page: 1 year: 2016 end-page: 22 article-title: New treatment strategies for alcohol‐induced heart damage publication-title: Int J Mol Sci – volume: 131: start-page: 1877 year: 2017 end-page: 1893 article-title: FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK‐paraoxonase 1 signaling axis in mice publication-title: Clin Sci (Lond) – volume: 49: start-page: 322 year: 2010 end-page: 329 article-title: Aldehyde dehydrogenase 2 knockout accentuates ethanol‐induced cardiac depression: role of protein phosphatases publication-title: J Mol Cell Cardiol – volume: 87: start-page: 2290 year: 2016 end-page: 2299 article-title: FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders publication-title: Neurology – volume: 104: start-page: 1663 year: 2018 end-page: 1669 article-title: National, regional and global mortality due to alcoholic cardiomyopathy in 2015 publication-title: Heart – volume: 19: start-page: 458 year: 2014 end-page: 469 article-title: Tissue‐specific loss of DARS2 activates stress responses independently of respiratory chain deficiency in the heart publication-title: Cell Metab – volume: 44: start-page: 992 year: 2008 end-page: 1001 article-title: Cardiac overexpression of alcohol dehydrogenase exacerbates chronic ethanol ingestion‐induced myocardial dysfunction and hypertrophy: role of insulin signaling and ER stress publication-title: J Mol Cell Cardiol – volume: 5: start-page: 107 year: 2014 article-title: FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases publication-title: Front Endocrinol (Lausanne) – volume: 121: start-page: 1638 year: 2002 end-page: 1650 article-title: Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology publication-title: Chest – volume: 310: start-page: H1658 year: 2016 end-page: H1670 article-title: Chronic plus binge ethanol feeding induces myocardial oxidative stress, mitochondrial and cardiovascular dysfunction, and steatosis publication-title: Am J Physiol Heart Circ Physiol – volume: 113: start-page: 14372 year: 2016 end-page: 14377 article-title: is associated with alcohol drinking, and its gene product β‐Klotho is necessary for FGF21 regulation of alcohol preference publication-title: Proc Natl Acad Sci U S A – volume: 6: start-page: 133 year: 2015 article-title: FGF21 and cardiac physiopathology publication-title: Front Endocrinol (Lausanne) – volume: 106: start-page: 19 year: 2015 end-page: 31 article-title: Fibroblast growth factor 21 protects the heart from oxidative stress publication-title: Cardiovasc Res – volume: 18: start-page: 307 year: 2013 end-page: 309 article-title: FGF21 mimetic shows therapeutic promise publication-title: Cell Metab – volume: 23: start-page: 344 year: 2016 end-page: 349 article-title: FGF21 regulates sweet and alcohol preference publication-title: Cell Metab – volume: 33: start-page: 851 year: 2015 end-page: 858 article-title: Myostatin and insulin‐like growth factor‐1 in hypertensive heart disease: a prospective study in human heart donors publication-title: J Hypertens – volume: 37: start-page: 1286 year: 2013 end-page: 1294 article-title: Activation of cardiac fibroblasts by ethanol is blocked by TGF‐β inhibition publication-title: Alcohol Clin Exp Res – volume: 117: start-page: 568 year: 2007 end-page: 575 article-title: ECM remodeling in hypertensive heart disease publication-title: J Clin Invest – volume: 59: start-page: 30 year: 2013 end-page: 40 article-title: Chronic ethanol consumption increases cardiomyocyte fatty acid uptake and decreases ventricular contractile function in C57BL/6J mice publication-title: J Mol Cell Cardiol – volume: 10: year: 2015 article-title: Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction publication-title: PLoS One – volume: 123: start-page: 327 year: 2011 end-page: 334 article-title: The progression of hypertensive heart disease publication-title: Circulation – volume: 25: start-page: 1045 year: 2017 end-page: 1053 article-title: FGF21 is a sugar‐induced hormone associated with sweet intake and preference in humans publication-title: Cell Metab – volume: 260: start-page: 163 year: 2018 end-page: 170 article-title: Autophagic control of cardiac steatosis through FGF21 in obesity‐associated cardiomyopathy publication-title: Int J Cardiol – volume: 104: start-page: 1987 year: 2018 end-page: 1988 article-title: Heartbeat: the worldwide burden of atrial fibrillation publication-title: Heart – volume: 6: year: 2016 article-title: Fibroblast growth factor 21 deficiency exacerbates chronic alcohol‐induced hepatic steatosis and injury publication-title: Sci Rep – volume: 248: start-page: 30 year: 2019 end-page: 40 article-title: Fibroblast growth factor‐21 protects against fibrosis in hypertensive heart disease publication-title: J Pathol – volume: 217: start-page: 287 year: 2016 end-page: 299 article-title: Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre‐diabetic rats publication-title: Acta Physiol (Oxf) – volume: 12: start-page: 572 year: 2020 article-title: The effects of ethanol on the heart: alcoholic cardiomyopathy publication-title: Nutrients – volume: 14: start-page: 32 year: 2015 article-title: Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients publication-title: Cardiovasc Diabetol – volume: 11: start-page: 884 year: 2010 end-page: 892 article-title: Alcoholic cardiomyopathy publication-title: J Cardiovasc Med (Hagerstown) – volume: 60: start-page: 977 year: 2014 end-page: 989 article-title: Fibroblast growth factor 21 protects against acetaminophen‐induced hepatotoxicity by potentiating peroxisome proliferator‐activated receptor coactivator protein‐1α‐mediated antioxidant capacity in mice publication-title: Hepatology – volume: 3: start-page: 78 year: 2015 end-page: 86 article-title: Natural history and prognostic factors in alcoholic cardiomyopathy publication-title: JACC Heart Fail – volume: 1687: start-page: 76 year: 2005 end-page: 83 article-title: Atorvastatin improves peroxisome proliferator‐activated receptor signaling in cardiac hypertrophy by preventing nuclear factor‐κB activation publication-title: Biochim Biophys Acta – volume: 6: start-page: 1395 year: 2017 end-page: 1406 article-title: Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury publication-title: Mol Metab – volume: 4: year: 2013 article-title: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice publication-title: Nat Commun – volume: 2: start-page: 1022 year: 2014 article-title: Alcoholic cardiomyopathy: multigenic changes underlie cardiovascular dysfunction publication-title: J Cardiol Clin Res – volume: 139: start-page: 212 year: 2018 end-page: 218 article-title: Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease publication-title: Cardiology – volume: 49: start-page: 1238 year: 2010 end-page: 1253 article-title: Cardiac overexpression of insulin‐like growth factor 1 attenuates chronic alcohol intake‐induced myocardial contractile dysfunction but not hypertrophy: roles of Akt, mTOR, GSK3β, and PTEN publication-title: Free Radic Biol Med – volume: 11: start-page: 96 year: 2018 end-page: 103 article-title: FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest publication-title: Mol Metab – ident: e_1_2_7_4_1 doi: 10.2459/JCM.0b013e32833833a3 – ident: e_1_2_7_17_1 doi: 10.1371/journal.pone.0129791 – ident: e_1_2_7_6_1 doi: 10.1136/heartjnl-2017-312384 – ident: e_1_2_7_31_1 doi: 10.1016/j.ijcard.2018.02.109 – ident: e_1_2_7_34_1 doi: 10.1016/j.yjmcc.2010.03.017 – ident: e_1_2_7_41_1 doi: 10.1016/j.cmet.2013.08.014 – ident: e_1_2_7_13_1 doi: 10.3389/fendo.2015.00133 – ident: e_1_2_7_37_1 doi: 10.3389/fendo.2014.00107 – ident: e_1_2_7_40_1 doi: 10.3390/nu12020572 – ident: e_1_2_7_11_1 doi: 10.1038/ncomms3019 – ident: e_1_2_7_21_1 doi: 10.1016/j.cmet.2015.12.008 – ident: e_1_2_7_33_1 doi: 10.1002/hep.27060 – ident: e_1_2_7_25_1 doi: 10.1016/j.yjmcc.2008.02.276 – ident: e_1_2_7_39_1 doi: 10.1016/j.cmet.2014.02.004 – ident: e_1_2_7_28_1 doi: 10.1172/JCI31044 – ident: e_1_2_7_16_1 doi: 10.1042/CS20170271 – ident: e_1_2_7_3_1 doi: 10.1378/chest.121.5.1638 – ident: e_1_2_7_38_1 doi: 10.1212/WNL.0000000000003374 – ident: e_1_2_7_12_1 doi: 10.1093/cvr/cvu263 – ident: e_1_2_7_26_1 doi: 10.1016/j.bbalip.2004.11.004 – ident: e_1_2_7_29_1 doi: 10.1111/acer.12111 – ident: e_1_2_7_14_1 doi: 10.1002/path.5226 – ident: e_1_2_7_30_1 doi: 10.1016/j.yjmcc.2013.02.005 – ident: e_1_2_7_27_1 doi: 10.1161/CIRCULATIONAHA.108.845792 – ident: e_1_2_7_2_1 doi: 10.1016/j.jchf.2014.07.014 – ident: e_1_2_7_19_1 doi: 10.1016/j.molmet.2018.03.010 – ident: e_1_2_7_23_1 doi: 10.1016/j.cmet.2017.04.009 – ident: e_1_2_7_18_1 doi: 10.1186/s12933-015-0190-7 – ident: e_1_2_7_8_1 doi: 10.3390/ijms17101651 – ident: e_1_2_7_5_1 doi: 10.1016/0002-8703(93)90175-9 – ident: e_1_2_7_24_1 doi: 10.1097/HJH.0000000000000493 – ident: e_1_2_7_9_1 doi: 10.1152/ajpheart.00214.2016 – ident: e_1_2_7_10_1 doi: 10.1016/j.freeradbiomed.2010.07.020 – ident: e_1_2_7_32_1 doi: 10.1016/j.molmet.2017.08.004 – ident: e_1_2_7_15_1 doi: 10.1159/000486127 – ident: e_1_2_7_20_1 doi: 10.1038/srep31026 – ident: e_1_2_7_22_1 doi: 10.1073/pnas.1611243113 – ident: e_1_2_7_7_1 doi: 10.1136/heartjnl-2018-314443 – ident: e_1_2_7_36_1 doi: 10.1111/apha.12698 – volume: 2 start-page: 1022 year: 2014 ident: e_1_2_7_35_1 article-title: Alcoholic cardiomyopathy: multigenic changes underlie cardiovascular dysfunction publication-title: J Cardiol Clin Res – reference: 33630303 - J Pathol. 2021 Jul;254(3):213-215 |
SSID | ssj0009955 |
Score | 2.457046 |
Snippet | Alcoholic cardiomyopathy (ACM) resulting from chronic alcohol misuse is one of the main contributors leading to heart failure and cardiovascular mortality.... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 198 |
SubjectTerms | alcohol Alcohol use alcoholic cardiomyopathy Animals Cardiomegaly - pathology Cardiomyopathy Cardiomyopathy, Alcoholic - complications Cardiomyopathy, Alcoholic - drug therapy Cardiomyopathy, Alcoholic - pathology Cardiovascular diseases Congestive heart failure FGF21 Fibroblast growth factors Fibroblast Growth Factors - genetics Fibroblast Growth Factors - metabolism Fibroblasts Fibrosis Growth factors heart Heart Failure - etiology Heart Failure - pathology Humans Hypertrophy Klotho protein Male Mice Mitochondria Mitochondria - pathology Myocardium Myocytes Myocytes, Cardiac - pathology Oxidative Stress Plasma levels Protective Agents - therapeutic use |
Title | The protective effect of fibroblast growth factor‐21 in alcoholic cardiomyopathy: a role in protecting cardiac mitochondrial function |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpath.5573 https://www.ncbi.nlm.nih.gov/pubmed/33125701 https://www.proquest.com/docview/2477814803 https://www.proquest.com/docview/2456410794 |
Volume | 253 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAXaMtr26UyiAOXbDeOHzGcKkS1QiqqqlbqoVLkV9pVaYLa7GE5ceuV38gvYSZOUhWKhLglyiS2k5nxN_H4G0LemOBLHXIB3o_rBLfNJhDZZglSUAbpBMtz3Ci8_1nOjvmnE3GyQt73e2EiP8Twww0to_XXaODGXu_ckoZixd6JEAqZPjFXCwHR4S11lNZCDEzhPFU9q9CU7Qx33p2L_gCYd_FqO-HsPSanfVdjnsnFZNHYifv2G4vjf45ljTzqgCjdjZqzTlZCtUEe7HdL7U_IDSgQ7VgcwCPSmPhB65KW0FRtAXU39AyC-OacxqI9P7__YCmdV9TEsrtzR12b7Xq5rLHp5TtqKGYzokz_5OosChlHL8G5gDOuPNoExQkXleYpOd77ePRhlnRVGxKXAXZMVGZ9KJHXjEtbQsSppfVKGglYQ4FeMGOsgihHp85xYYKVXllpU-lcWk49z56R1aquwgtCPYfT3KqUOc-Z8UaWmhnOuJ_aoKUbkbf99ytcR2mOlTW-FJGMmRU4ugJf7Ii8HkS_Rh6P-4TGvRIUnSlfF4wrpAXLp3D51XAZjBBXVkwV6gXKCMkhkNZ8RJ5H5RlaybIUKwWm0NlWBf7efHGwezTDg81_F90iDxlm2bR55GOy2lwtwkuASY3dbu3hF4JREeY |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o-FAgZx4JLtxrGdGHGpENUC3QqhrdQLivxKqaAJguyhnLhx5TfyS5iJk1TlISFuiTzJ2MnMeMYefwPwyARf6VBItH5CJ3RsNsHINksIgjIoJ3lR0EHhxa6a74mX-3J_DZ4OZ2EiPsS44Eaa0dlrUnBakN48QQ2lkr1TKfPsDJylit5dQPXmBDxKaylHrHCR5gOu0Ixvjo-eno1-czFPe6zdlLN9Cd4OnY2ZJu-nq9ZO3ZdfcBz_dzSX4WLvi7KtKDxXYC3UV-Hcot9tvwbfUIZYD-SARpHF3A_WVKxCXo1Fx7tlBxjHt-9YrNvz4-t3nrLDmplYeffQMdclvB4dN8T6-AkzjBIaiWZ4c30QiYxjR2hf0B7XntSC0ZxLcnMd9rafL5_Nk75wQ-IydB-TPLM-VARtJpStMOjUyvpcGYXuRo6iwY2xOQY6OnVOSBOs8rlVNlXOpdXMi-wGrNdNHW4B8wJvC5un3HnBjTeq0twILvzMBq3cBB4PP7B0Pao5Fdf4UEY8Zl7S6Er6sBN4OJJ-jFAefyLaGKSg7LX5c8lFTshgxQybH4zNqIe0uWLq0KyIRiqBsbQWE7gZpWfkkmUpFQtMsbOdDPydffl6azmni9v_Tnofzs-Xi51y58XuqztwgVPSTZdWvgHr7adVuIteU2vvdcrxE35lFgE |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwELZKkSou7JQHBQziwCWvieMlhlNFeXosrSrUSj0gRd5SKtqkKnmHcuLGld_IL2EmTlKVRULcEmUS28k345l4_A0hT03wlQ6FAOvHdYLbZhOIbPMEKSiDdIIVBW4U3tqW8z3-Zl_sL5EXw16YyA8x_nBDzejsNSr4ia_Wz0lDsWLvVAiVXyKXuUwLhPTm-3PuKK2FGKnCeaYGWqGUrY-3XpyMfvMwLzqs3Ywzu0Y-DH2NiSafpovWTt2XX2gc_3Mw18nV3hOlGxE6N8hSqG-Sla1-rf0W-QYIoj2NA5hEGjM_aFPRCppqLLjdLT2AKL79SGPVnh9fv7OMHtbUxLq7h466Lt31-KzBps-eU0MxnRFlhifXB1HIOHoM1gWsce1RKSjOuIia22Rv9mr35TzpyzYkLgfnMVG59aFCYjMubQUhp5bWK2kkOBsKgMGMsQrCHJ05x4UJVnplpc2kc1mVep7fIct1U4e7hHoOp4VVGXOeM-ONrDQznHGf2qClm5Bnw_crXc9pjqU1jsrIxsxKHF2JL3ZCnoyiJ5HI409CawMIyl6XP5eMK-QFK1K4_Hi8DFqISyumDs0CZYTkEElrPiGrETxjK3meYanADDrbQeDvzZc7G7tzPLj376KPyMrO5qx893r77X1yhWHGTZdTvkaW29NFeAAuU2sfdqrxE1eoFLk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+protective+effect+of+fibroblast+growth+factor%E2%80%9021+in+alcoholic+cardiomyopathy%3A+a+role+in+protecting+cardiac+mitochondrial+function&rft.jtitle=The+Journal+of+pathology&rft.au=Gemma+Ferrer%E2%80%90Curriu&rft.au=Mariona+Guitart%E2%80%90Mampel&rft.au=Rup%C3%A9rez%2C+Celia&rft.au=Zamora%2C+Monica&rft.date=2021-02-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0022-3417&rft.eissn=1096-9896&rft.volume=253&rft.issue=2&rft.spage=198&rft.epage=208&rft_id=info:doi/10.1002%2Fpath.5573&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3417&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3417&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3417&client=summon |